Pharmafile Logo
Pharmafocus logo
Advanced Search

Amarna Therapeutics and NorthX Biologics collaborate to advance gene therapy for type 1 diabetes

July 10, 2025
Mergers and Acquisitions, Research and Development Amarna Therapeutics, Diabetes, Immunology, NorthX Biologics, Type 1 diabetes, gene therapy, immune-mediated diseases

Amarna Therapeutics and NorthX Biologics have finalised an agreement to accelerate the development of Nimvec AM510, a gene therapy targeting …

News

Eppendorf Award for Young European Investigators 2025 awarded to neuroscientist Varun Venkataramani

July 10, 2025
Medical Communications, Medical/ Scientific Writing, Research and Development Neurology, Oncology

Varun Venkataramani, of Heidelberg University Hospital, Germany, has been awarded the 2025 Eppendorf Award for Young European Investigators for his …

News
Mosquito image

First malaria medicine for infants under 4.5kg receives approval

July 9, 2025
Medical Communications, Research and Development Coartem Baby, Infections and infestations, Medicines for Malaria Venture, Novartis, Paediatrics, Swissmedic, malaria

Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine for newborns and young infants. …

News
Patients image

First adult in the UK given new treatment for type 1 diabetes

July 9, 2025

The first adult in the UK to trial Tepilzumab for type 1 diabetes has started treatment at the Royal Devon …

News

Richard Philipson appointed as chief medical officer of Hansa Biopharma

July 9, 2025
Research and Development Hansa Biopharma, Immunology, chief medical officer, immunology

Hansa Biopharma has announced that Richard Philipson has been appointed chief medical officer, effective 14 July. Philipson will join the …

Appointment
money-2180330_960_720

Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy

July 9, 2025
Research and Development Ciloa, Diabetes, France 2030, Obesity, adiponectin, funding, obesity, type 2 diabetes

French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its lead candidate, APN-sEV, targeting obesity …

News
brain_scan_small

Duke Street Bio receives FDA fast track designation for brain metastases treatment

July 8, 2025
Medical Communications, Research and Development Duke Street Bio, Oncology, US Food and Drug Administration, brain metastases, breast cancer, fast track designation

Duke Street Bio, a biotech company based in London, UK, has announced that the US Food and Drug Administration (FDA) …

News
senior-woman-suffering-from-knee-pain-home_61573-2004

SMC recommends Eladynos for postmenopausal osteoporosis in Scotland

July 8, 2025
Medical Communications, Research and Development Musculo-skeletal disorder, NHS, Scottish Medicine Consortium, Theramex, clinical trials, osteoporosis, postmenopause

Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for NHS use …

News
obesity

Pila Pharma raises SEK 20m to advance new oral obesity treatment

July 8, 2025
Research and Development Novo Nordisk, Obesity, Ozempic, Pila Pharma, Wegovy, obesity, semaglutide, type 2 diabetes

Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development …

News

HeartBeat.bio and biotx.ai partner to develop new drugs for heart failure

July 7, 2025
Mergers and Acquisitions, Research and Development AI, Cardiology, HeartBeat.bio, biotx.ai, heart failure

HeartBeat.bio and biotx.ai have entered a partnership to accelerate heart failure drug discovery by combining AI-driven genetics with human cardiac …

News

T-cell therapy – the evolution of cancer treatments

July 7, 2025
CERo therapeutics, Cancer, T cell, immunotherapy

The current forms of immunotherapy, how T cell therapy works and what the future holds

Feature
Astra Zeneca Logo

Purpose and people: the enduring power of brand and the evolution of employer identity

July 7, 2025
Branding, Business Services, Corporate Branding, Medical Communications, Sales and Marketing AstraZeneca, Identity, Inclusion, The Caffeine Partnership, benenden health, branding

Two decades ago, terms like purpose and people were rarely at the forefront of branding conversations. The focus was on …

Feature
Endometriosis - Woman holding stomach in pain

The Problem of Endometriosis in the UK

July 7, 2025
Research and Development NHS, Obstetrics & Gynaecology, Pain, Reproductive health, Theramex, endometriosis, gynaecology

When did we decide it was an acceptable condition of womanhood in the UK to live with chronic pain?

Feature
Toast Burning

Five facts about UV exposure and sun safety

July 7, 2025
Medical Communications Dermatology, Five Facts, Oncology, Skin, melanoma, skincare

1We can acclimatise to UV exposure. For example, we’re more likely to burn if there’s a sunny spell earlier in …

Feature

LEO Pharma appoints Helle Hedegaard Juhl as EVP of global people & corporate affairs

July 7, 2025
Manufacturing and Production Dermatology, Helle Hedegaard Juhl, LEO Pharma, Skin, dermatology

Danish dermatology company, LEO Pharma, announced the appointment of new executive vice president (EVP) of global people and corporate affairs, …

Appointment
Jens Holstein, Alexandra Ogilvie and Ulrich Dauer

Mallia strengthens its advisory board as it accelerates hair loss treatment

July 7, 2025
Manufacturing and Production Dermatology, Skin, biopharma, dermatology, hair loss, mallia

German dermatology company, Mallia Innovations, has appointed Jens Holstein, Alexandra Ogilvie and Ulrich Dauer to its advisory board, strengthening its …

Appointment

FDA grants accelerated approval for advanced non-small cell lung cancer treatment

July 4, 2025
Medical Communications, Research and Development Breakthrough Therapy Designation, Oncology, US Food and Drug Administration, Zegfrovy, clinical trial, non-small cell lung cancer, priority review

The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy (sunvozertinib) for the treatment of …

News

The quiet crisis: why medicines operations matter more than ever in the ICB era

July 4, 2025
Business Services, Market Access Gateway to Local Adoption, Integrated Care Board, NHS, Primary Care Networks, Visions4Health

In the second of the Gateway to Local Access series, Vision4Health caught up with Dr Graham Duce, ICB GP Prescribing …

Feature

Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment

July 4, 2025
Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer

Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …

News

Nick Challoner appointed CEO of Ingenza to drive further growth

July 4, 2025
Business Services, Manufacturing and Production CEO, Corporate, Ingenza, contract research development and manufacturing organisation (CRDMO), president

Ingenza, a Scottish contract research, development and manufacturing organisation (CRDMO), has announced the appointment of Nick Challoner as chief executive …

Appointment
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026